.Attributes Medicine, Released online: 09 Oct 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec received FDA confirmation after a damaging trial, which highlights the various complications and also difficulties of medication progression in this particular environment.